Professor Sabine Bahn MD, Ph.D, MRCPsych, the group leader, has an established international reputation and been invited to speak at many national and international meetings and the group has an extensive list of academic and media publications. In 2005 a spin-out company, PsyNova Neurotech Ltd, was established to commercialise the findings of the CCNR and provide a conduit for translating our discoveries to the clinic.
- Published over 100 peer reviewed papers over the last 3 years, most of them in high-impact journals.
- First to deliver multi-dimensional molecular evidence for a disturbance of cerebral energy metabolism and oxidative stress in schizophrenia based on post mortem analyses - PMID:15098003.
- Patient stratification: insulin resistance is found in drug naive first onset schizophrenia (not only associated with antipsychotics treatment – as commonly thought) - PMID:20098438.
- In June 2011, Psynova and Rules Based Medicine have been acquired by Myriad Genetics Inc. (a NASDAQ-listed company).
- Bahn lab and Psynova established global (Europe /US) clinical and academic network to facilitate the development and standardisation of biomarkers for mental disorders
- Brain/blood molecular signatures/pathways underpinning 25 pre-clinical models of schizophrenia and MDD leading to the identification of 4 schizophrenia and 2 MDD rodent models most similar to the human disease
- In 2010 the Bahn lab and PSY, together with its partner company Myriad RBM Inc have launched the first commercially available aid for the diagnosis of schizophrenia.
- First to identify reproducible protein biomarkers for schizophrenia in blood, which has led to the formation of a University of Cambridge spin-out company, Psynova Neurotech Ltd (PSY), in 2005 - PMID: 21483431.
- Provided the first molecular evidence that schizophrenia and bipolar affective disorder are related disorders (Lancet/2003)
- Sabine Bahn was elected, amongst 5 other scientists, to represent the “Human Face of Science in Europe” by the European Commission in 2004.
- Bahn lab/Psynova work has received substantial media interest, notably in the BBC, Nature, Science, national and international newspapers, television, patient groups and mental health charities, TIME magazine, Times Higher Education, Scientific American and New Scientist.